Rayno Life Science Portfolio Update: ALR, GPRO, REGN
Consolidation Continues in Mid Cap DX Companies: Bull Market in Biotech Hits New Highs Our Life Science Tools and Diagnostics Portfolio had a nice hit today with GenProbe up 18.75% on the Agreement that it would be sold to Hologic (HOLX $18.82 down 11.2%) for $3.7B or $82.75/sh. This is a...
Biopharmaceuticals Resist Market Correction: M&A du jour Ardea (RDEA)
Biotech Outperforming Tech Lately: M&A Hit of the Day Ardea Biosciences The market continues its choppy trend with the QQQ's off 0.9% to $65 with some Internet high fliers like AMZN and NFLX taking a hit. But biotech recovered from earlier losses with the IBB down only 0.35% and...
Rayno Life Science Portfolio: CBST, GILD,HGSI, REGN SQNM
Biotech Rally Ignited By Clinical News and M&A Theme The biotech sector roared back today with major ETF's IBB ($122) up 2.4% and XBI ($78.6) up 5.1 % driven primarily by Gilead (GILD $52.23) up 12 % and other large caps like Regeneron (REGN $127) up 2.5%. Gilead (GILD) was up on clinical...
Risk Off: Profit Taking, Spain and Jobs Data//BIO Update April 11
Nice Recovery in biotech today with our mid-cap index up almost 1%. Without doing a lot of detailed analysis it looks like stocks that have major institutional sponsors are rallying. Smaller caps without significant volume are still lagging. Two high fliers : Vivus (VVUS $22.15) and Medivation...
Financial Review of Pure Play Clinical Diagnostic Companies
Who to Watch Among the Pure Play DX Companies? High fliers with cache' among traders and investors: CPHD,EXAS. Value plays for earnings turn-around: ALR, QGEN. Niche companies: NEOG, SQNM. Personalized medicine plays: GHDX, QGEN. M&A potential? Very quiet lately. Whale deal for 2012:...